Scaling direct-to-consumer (DTC) campaigns has never been more complex. Pharma and med device marketers must prove ROI, maximize media efficiency, and deliver script lift or case growth, all while protecting sensitive health data. With regulators tightening enforcement, patients demanding trust, and legacy marketing stacks unfit for healthcare, the risks are higher than ever. In fact, according to Deloitte, 73% of healthcare marketers cite data privacy as their #1 barrier to DTC innovation.

To thrive in today’s environment, pharma and med device marketers must embrace a privacy-first performance mindset: treating compliant first-party data as a strategic growth asset, not a constraint. This requires tighter alignment between marketing, IT, privacy and compliance functions to establish shared visibility, clear guardrails, and agile processes. The path forward isn’t about slowing down campaigns, but about re-engineering them for transparency, trust, and efficiency. Turning privacy into a competitive differentiator, reassuring patients while also empowering marketing teams to execute with speed.

Join thought leaders from Freshpaint along with a group of likeminded peers, as we discuss emerging best practices, share cautionary tales, and co-develop strategies for making DTC marketing both safer and more impactful.

Freshpaint’s Healthcare Privacy Platform helps life science brands transform performance marketing into a direct-to-consumer growth engine, without privacy risk. By replacing non-compliant tracking, Freshpaint enables marketers to measure ROI with precision, drive device fulfillment and script lift, and deliver personalized digital journeys, all while ensuring compliance with HIPAA, evolving state privacy laws, and FTC consumer data protections.